> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bavarian Nordic Sells Priority Voucher for $160 Million
- URL: https://www.fdaweb.com/bavarian-nordic-sells-priority-voucher-for-160-million/
- Published: 2025-06-18T12:00:00.000Z
- Updated: 2026-09-14T15:14:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159378

Bavarian Nordic says it has entered into an agreement with an undisclosed buyer to sell for $160 million a priority review voucher that was awarded for gaining approval of its chikungunya vaccine Vimkunya ([see earlier story](https://www.bavarian-nordic.com/investor/news/news.aspx?news=7053&ref=fdaweb.com)). Under a license agreement when the company acquired the rights to the vaccine in 2023, the National Institutes of Health will receive 20% of the gross proceeds from the voucher’s sale. “The transaction remains subject to customary closing conditions, including anti-trust review, which is expected to occur in the third quarter of 2025,” the company says.